寡转移性NSCLC全身联合局部治疗的临床研究进展
Progress of Clinical Research on Systemic Combined Local Treatment for Oligometastatic NSCLC
DOI: 10.12677/ACM.2023.1391938, PDF,   
作者: 刘润莎：西安医学院研究生处，陕西 西安；张燕军*：陕西省肿瘤医院内三科，陕西 西安
关键词: 非小细胞肺癌；寡转移；局部治疗；系统治疗；Non-Small Cell Lung Cancer； Oligometastasis； Local Therapy； Systemic Therapy
摘要: 寡转移非小细胞肺癌是IV期非小细胞肺癌患者发生有限的部位和数量的转移，可能比广泛转移性具有更惰性的生物学特性，其预后比广泛性转移要好。寡转移可能受益于局部积极治疗，但目前关于寡转移性NSCLC针对转移灶治疗(metastasis directed therapy, MDT)的专家共识，缺少随机对照III期临床试验等高级别的循证医学证据。本文拟从肿瘤内科的角度，就寡转移性NSCLC不同系统治疗联合MDT的临床研究现状、影响因素作一系统回顾。
Abstract: Oligometastatic non-small cell lung cancer is stage IV non-small cell lung cancer with limited site and number of metastases that may have a more inert biology than extensive metastasis and a bet-ter prognosis than extensive metastasis. Oligometastasis may benefit from locally positive treat-ment, but the current expert consensus on metastasis directed therapy (MDT) for oligometastasis in NSCLC lacks high-level evidence-based medical evidence such as randomized controlled phase III clinical trials. From the perspective of medical oncology, this paper reviews the clinical research status and influencing factors of different systems of treatment combined with MDT for oligometa-static NSCLC.
文章引用：刘润莎, 张燕军. 寡转移性NSCLC全身联合局部治疗的临床研究进展[J]. 临床医学进展, 2023, 13(9): 13863-13873. https://doi.org/10.12677/ACM.2023.1391938

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Chen, L., Hou, Y., Xia, Y., et al. (2020) Radiotherapy Dose and In-duction Chemotherapy Cycles Are Associated with Prognosis and Toxicity Risk: A Retrospective Study of 227 Patients with Unresectable Stage III Non-Small-Cell Lung Cancer. Technology in Cancer Research & Treatment, 19, 1-8. [Google Scholar] [CrossRef] [PubMed]
[3] Zhou, C., Wu, Y., Chen, G., et al. (2015) BEYOND: A Ran-domized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients with Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 33, 2197-2204. [Google Scholar] [CrossRef] 
[4] Gridelli, C., Maione, P. and Rossi, A. (2013) The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed versus Placebo Immediately Following Induction First-Line Treatment with Pemetrexed plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer. Reviews on Recent Clinical Trials, 8, 23-28. [Google Scholar] [CrossRef] [PubMed]
[5] Lu, J., Chu, T., Liu, H., et al. (2022) Equivalent Efficacy Assessment of QL1101 and Bevacizumab in Nonsquamous Non-Small Cell Lung Cancer Patients: A Two-Year Fol-low-Up Data Update. Chinese Journal of Cancer Research, 34, 28-39. [Google Scholar] [CrossRef] [PubMed]
[6] Christ, S.M., Pohl, K., Muehlematter, U.J., et al. (2022) Imaging-Based Prevalence of Oligometastatic Disease: A Single-Center Cross-Sectional Study. International Journal of Radiation Oncology Biology Physics, 114, 596-602. [Google Scholar] [CrossRef] [PubMed]
[7] Torok, J.A., Gu, L., Tandberg, D.J., et al. (2017) Patterns of Distant Metastases after Surgical Management of Non- Small-Cell Lung Cancer. Clinical Lung Cancer, 18, e57-e70. [Google Scholar] [CrossRef] [PubMed]
[8] Rusthoven, K.E., Hammerman, S.F., Kavanagh, B.D., et al. (2009) Is There a Role for Consolidative Stereotactic Body Radiation Therapy Following First-Line Systemic Therapy for Meta-static Lung cancer? A Patterns-of-Failure Analysis. Acta Oncologica, 48, 578-583. [Google Scholar] [CrossRef] [PubMed]
[9] Tran, P.T., Sutera, P., Phillips, R.M., et al. (2022) From Idea to Clinical Practice: A Brief History of Oligometastatic Disease. International Journal of Radiation Oncology, Biology, Physics, 114, 576-580. [Google Scholar] [CrossRef] [PubMed]
[10] Milano, M.T., Biswas, T., Simone, C.N., et al. (2021) Oligome-tastases: History of a Hypothesis. Annals of Palliative Medicine, 10, 5923-5930. [Google Scholar] [CrossRef] [PubMed]
[11] Gutiontov, S.I., Pitroda, S.P., Tran, P.T., et al. (2021) (Oli-go)metastasis as a Spectrum of Disease. Cancer Research, 81, 2577-2583. [Google Scholar] [CrossRef] 
[12] Guckenberger, M., Lievens, Y., Bouma, A.B., et al. (2020) Characterisation and Classification of Oligometastatic Disease: A European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer Consensus Recommendation. The Lancet Oncology, 21, e18-e28. [Google Scholar] [CrossRef] 
[13] Lievens, Y., Guckenberger, M., Gomez, D., et al. (2020) Defining Oligometastatic Disease from a Radiation Oncology Perspective: An ESTRO-ASTRO Consensus Document. Radiotherapy and Oncology, 148, 157-166. [Google Scholar] [CrossRef] [PubMed]
[14] Iyengar, P., All, S., Berry, M.F., et al. (2023) Treatment of Oli-gometastatic Non-Small Cell Lung Cancer: An ASTRO/ ESTRO Clinical Practice Guideline. Practical Radiation Oncol-ogy. [Google Scholar] [CrossRef] [PubMed]
[15] Kroeze, S.G.C., Pavic, M., Stellamans, K., et al. (2023) Me-tastases-Directed Stereotactic Body Radiotherapy in Combination with Targeted Therapy or Immunotherapy: Systematic Review and Consensus Recommendations by the EORTC-ESTRO OligoCare Consortium. The Lancet Oncology, 24, e121-e132. [Google Scholar] [CrossRef] 
[16] Kwint, M., Walraven, I., Burgers, S., et al. (2017) Outcome of Radical Local Treatment of Non-Small Cell Lung Cancer Patients with Synchronous Oligometastases. Lung Cancer (Amsterdam, Netherlands), 112, 134-139. [Google Scholar] [CrossRef] [PubMed]
[17] Xu, Q., Zhou, F., Liu, H., et al. (2018) Consolidative Local Ablative Therapy Improves the Survival of Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Acti-vating Mutation Treated with First-Line EGFR-TKIs. Journal of Thoracic Oncology, 13, 1383-1392. [Google Scholar] [CrossRef] [PubMed]
[18] Mitchell, K.G., Farooqi, A., Ludmir, E.B., et al. (2021) Pulmonary Resection Is Associated with Long-Term Survival and Should Remain a Therapeutic Option in Oligometastatic Lung Cancer. The Journal of Thoracic and Cardiovascular Surgery, 161, 1497-1504. [Google Scholar] [CrossRef] [PubMed]
[19] Ni, Y., Peng, J., Yang, X., et al. (2021) Multicentre Study of Mi-crowave Ablation for Pulmonary Oligorecurrence after Radical Resection of Non-Small-Cell Lung Cancer. British Jour-nal of Cancer, 125, 672-678. [Google Scholar] [CrossRef] [PubMed]
[20] Kodama, H., Yamakado, K., Takaki, H., et al. (2012) Lung Ra-diofrequency Ablation for the Treatment of Unresectable Recurrent Non-Small-Cell Lung Cancer after Surgical Interven-tion. CardioVascular and Interventional Radiology, 35, 563-569. [Google Scholar] [CrossRef] [PubMed]
[21] Wei, Z., Ye, X., Yang, X., et al. (2019) Efficacy and Safety of Microwave Ablation in the Treatment of Patients with Oligometastatic Non-Small-Cell Lung Cancer: A Retrospective Study. International Journal of Hyperthermia, 36, 826-833. [Google Scholar] [CrossRef] [PubMed]
[22] Ni, Y., Bi, J., Ye, X., et al. (2016) Local Microwave Abla-tion with Continued EGFR Tyrosine Kinase Inhibitor as a Treatment Strategy in Advanced Non-Small Cell Lung Cancers That Developed Extra-Central Nervous System Oligoprogressive Disease during EGFR Tyrosine Kinase Inhibitor Treatment: A Pilot Study. Medicine (Baltimore), 95, e3998. [Google Scholar] [CrossRef] 
[23] 刘宝东, 刘磊, 胡牧, 等. 肺癌切除术后肺内孤立性转移复发灶的射频消融治疗[J]. 中国肺癌杂志, 2014, 17(6): 460-464.
[24] Ni, Y., Liu, B., Ye, X., et al. (2019) Local Thermal Ablation with Continuous EGFR Tyrosine Kinase In-hibitors for EGFR-Mutant Non-Small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oli-goprogressive Disease. Cardiovascular and Interventional Radiology, 42, 693-699. [Google Scholar] [CrossRef] [PubMed]
[25] Li, X., Zhao, M., Wang, J., et al. (2013) Percutaneous CT-Guided Radiofrequency Ablation as Supplemental Therapy after Systemic Chemotherapy for Selected Advanced Non-Small Cell Lung Cancers. American Journal of Roentgenology (1976), 201, 1362. [Google Scholar] [CrossRef] 
[26] Schoellnast, H., Deodhar, A., Hsu, M., et al. (2012) Recurrent Non-Small Cell Lung Cancer: Evaluation of CT-Guided Radiofrequency Ablation as Salvage Therapy. Acta Radiologica (1987), 53, 893-899. [Google Scholar] [CrossRef] [PubMed]
[27] 刘宝东, 李元博, 胡牧, 等. 射频消融在EGFR-TKIs治疗非小细胞肺癌后局部进展的初步临床应用[J]. 中国肺癌杂志, 2016, 19(12): 859-863.
[28] Iyengar, P., Wardak, Z., Gerber, D.E., et al. (2018) Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Random-ized Clinical Trial. JAMA Oncology, 4, e173501. [Google Scholar] [CrossRef] [PubMed]
[29] Gomez, D.R., Blumenschein, G.R., Lee, J.J., et al. (2016) Local Consolidative Therapy versus Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer without Progression after First-Line Systemic Therapy: A Multicentre, Randomised, Controlled, Phase 2 Study. The Lancet Oncology, 17, 1672-1682. [Google Scholar] [CrossRef] 
[30] Gomez, D.R., Tang, C., Zhang, J., et al. (2019) Local Con-solidative Therapy vs. Maintenance Therapy or Observation for Patients with Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 37, 1558-1565. [Google Scholar] [CrossRef] 
[31] Wang, X., Bai, Y., Verma, V., et al. (2023) Randomized Trial of First-Line Tyrosine Kinase Inhibitor with or without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer. JNCI: Journal of the National Cancer Institute, 115, 742-748. [Google Scholar] [CrossRef] [PubMed]
[32] Theelen, W.S.M.E., Chen, D., Verma, V., et al. (2021) Pembrolizumab with or without Radiotherapy for Metastatic Non-Small-Cell Lung Cancer: A Pooled Analysis of Two Randomised Trials. The Lancet Respiratory Medicine, 9, 467-475. [Google Scholar] [CrossRef] 
[33] Theelen, W., Peulen, H., Lalezari, F., et al. (2019) Effect of Pembrolizumab after Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial. JAMA Oncology, 5, 1276-1282. [Google Scholar] [CrossRef] [PubMed]
[34] Petrelli, F., Ghidini, A., Cabiddu, M., et al. (2018) Addition of Radiotherapy to the Primary Tumour in Oligometastatic NSCLC: A Systematic Review and Meta-Analysis. Lung Cancer (Amsterdam, Netherlands), 126, 194-200. [Google Scholar] [CrossRef] [PubMed]
[35] Bauml, J.M., Mick, R., Ciunci, C., et al. (2019) Pembrolizumab after Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial. JAMA Oncology, 5, 1283-1290. [Google Scholar] [CrossRef] [PubMed]
[36] Katipally, R.R., Pitroda, S.P., Juloori, A., et al. (2022) The Oli-gometastatic Spectrum in the Era of Improved Detection and Modern Systemic Therapy. Nature Reviews. Clinical On-cology, 19, 585-599. [Google Scholar] [CrossRef] [PubMed]
[37] Garde-Noguera, J., Martin-Martin, M., Obeso, A., et al. (2022) Current Treatment Landscape for Oligometastatic Non-Small Cell Lung Cancer. World Journal of Clinical Oncology, 13, 485-495. [Google Scholar] [CrossRef] [PubMed]
[38] Jasper, K., Stiles, B., McDonald, F., et al. (2022) Practical Manage-ment of Oligometastatic Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 40, 635-641. [Google Scholar] [CrossRef] 

为你推荐